Editorial: Community series in primary immunodeficiencies worldwide, volume III
-
By
-
Hirokazu Kanegane
-
Antonio Condino-Neto
-
Jolan E. Walter
-
June 30, 2026
-
Clinical Scorecard: Global Perspectives on Primary Immunodeficiencies, Volume III
At a Glance
| Category | Detail |
|---|
| Condition | Primary Immunodeficiencies (PIDs) |
| Key Mechanisms | Impaired immune function leading to increased susceptibility to infections and autoimmune diseases. |
| Target Population | Individuals with genetic predispositions to immune dysfunction. |
| Care Setting | Clinical practice and genetic testing environments. |
Key Highlights
- Over 500 PIDs identified, with autoimmune diseases as common manifestations.
- Newborn screening programs can identify PIDs early, such as SCID.
- Genetic testing is crucial for diagnosing conditions like LRBA and MAGT1 deficiencies.
- Early diagnosis of GATA2 deficiency can prevent severe hematological complications.
- X-linked hyper-IgM syndrome presents atypically due to specific genetic variants.
Guideline-Based Recommendations
Diagnosis
- Utilize comprehensive screening and genetic testing for early identification of PIDs.
Management
- Consider targeted therapies such as abatacept and HSCT for specific deficiencies.
Monitoring & Follow-up
- Regular assessment of immunoglobulin levels in patients with HLH.
Risks
- Increased risk of severe infections and autoimmune manifestations in undiagnosed PIDs.
Patient & Prescribing Data
Patients with diagnosed PIDs requiring specialized treatment.
Targeted therapies and HSCT can significantly improve outcomes.
Clinical Best Practices
- Implement newborn screening programs to detect PIDs early.
- Conduct genetic testing for family history of immune disorders.
- Monitor for autoimmune symptoms as potential early indicators of PIDs.
Related Resources & Content
